Started in 2024, Bambusa secured its lead drug candidates through its earlier acquisition of assets from a unit of BioNTech SE, the first to treat atopic dermatitis, commonly known as eczema, and the second to treat other inflammatory disorders including respiratory and allergic diseases.
Started in 2024, Bambusa secured its lead drug candidates through its earlier acquisition of assets from a unit of BioNTech SE, the first to treat atopic dermatitis, commonly known as eczema, and the second to treat other inflammatory disorders including respiratory and allergic diseases.
<iframe src="https://hindustansphere.com/embed/cluster/d41a4553fc1ae225991ca6f3d04e0a2c1ea62c8e" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Bambusa Therapeutics Files for IPO To Fund Eczema Drug Trials"></iframe>
